Last $29.56 USD
Change Today -0.82 / -2.70%
Volume 436.2K
ACOR On Other Exchanges
As of 8:10 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $39.95
52 Week Low
01/7/14 - $27.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acorda therapeutics inc (ACOR) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (ACOR) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company’s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for the treatment of injuries to the brain and spinal cord, as well as other neurotraumatic indications. The company was founded in 1995 and is headquartered in Ardsley, New York.

421 Employees
Last Reported Date: 03/3/14
Founded in 1995

acorda therapeutics inc (ACOR) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $720.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $193.9K
Chief of Business Operations
Total Annual Compensation: $312.7K
General Counsel, Corporate Secretary and Pres...
Total Annual Compensation: $517.7K
Chief Medical Officer
Total Annual Compensation: $418.5K
Compensation as of Fiscal Year 2013.

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. to Initiate Phase 3 Clinical Trial, Studying Use of Dalfampridine Administered Twice Daily to Improve Walking in People Who Experienced Stroke

Acorda Therapeutics, Inc. expects to initiate a Phase 3 clinical trial by the end of this year studying the use of dalfampridine administered twice daily (BID) to improve walking in people who have experienced a stroke. The company has been exploring a once-daily (QD) formulation of dalfampridine for use in the post-stroke clinical program. Based on the results of an in-vitro alcohol dose dumping study and a subsequent fed-fasted study, the company has determined that the current QD formulation is not practical for further testing. The company is working with external partners to develop a new QD formulation that could be included in future post-stroke clinical trials.

Acorda Therapeutics Seeks Acquisitions

Acorda Therapeutics, Inc. (NasdaqGS:ACOR) seeks acquisitions. Acorda Therapeutics intends to offer $300 million principal amount of convertible senior notes due 2021 and grant the underwriter an option to purchase up to an additional $45 million principal amount. Acorda Therapeutics plans to use the net proceeds from the offering for general corporate purposes, to fund possible acquisitions of, or investments in, complementary businesses, products and technologies.

Acorda Therapeutics Considers Acquisitions

Acorda Therapeutics, Inc. (NasdaqGS:ACOR) to considers acquisitions. Michael Rogers, Chief Financial Officer of Acorda, said, "We are in a very strong financial position and we would like to fill in our pipeline of products with later stage products, potentially even an in-market product. So we are spending a good deal of our time looking at assets to in-license or acquire, both in neurology and potentially slightly outside of neurology. We think we've got a very good specialty commercial organization. Our focus is in neurology, but we are looking as well outside."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $29.56 USD -0.82

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $336.79 USD -0.81
Durect Corp $1.51 USD -0.05
Novartis AG SFr.80.40 CHF +0.20
Teva Pharmaceutical Industries Ltd $54.40 USD -0.65
View Industry Companies

Industry Analysis


Industry Average

Valuation ACOR Industry Range
Price/Earnings 70.3x
Price/Sales 3.6x
Price/Book 2.8x
Price/Cash Flow 69.2x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at